Evidence map›Paper›PMID 32163234›Full record

ArticleStem cells translational medicine2020

Cystic renal-epithelial derived induced pluripotent stem cells from polycystic kidney disease patients.

Annegien T Kenter, Eveline Rentmeester, Job van Riet, Ruben Boers, Joachim Boers, Mehrnaz Ghazvini, Vanessa J Xavier, Geert J L H van Leenders, Paul C M S Verhagen, Marjan E van Til and 10 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Recent Discoveries in Epigenetic Modifications of Polycystic Kidney Disease.International journal of molecular sciences · 2021
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Annegien T KenterDepartment of Developmental Biology, Erasmus Medical Center Rotterdam (EMC), Oncode Institute, Rotterdam, The Netherlands.
Eveline RentmeesterDepartment of Developmental Biology, Erasmus Medical Center Rotterdam (EMC), Oncode Institute, Rotterdam, The Netherlands.
Job van RietCancer Computational Biology Center, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Ruben BoersDepartment of Developmental Biology, Erasmus Medical Center Rotterdam (EMC), Oncode Institute, Rotterdam, The Netherlands.
Joachim BoersDepartment of Developmental Biology, Erasmus Medical Center Rotterdam (EMC), Oncode Institute, Rotterdam, The Netherlands.
Mehrnaz GhazviniDepartment of Developmental Biology, Erasmus Medical Center Rotterdam (EMC), Oncode Institute, Rotterdam, The Netherlands.
Vanessa J XavierDepartment of Developmental Biology, Erasmus Medical Center Rotterdam (EMC), Oncode Institute, Rotterdam, The Netherlands.
Geert J L H van LeendersDepartment of Pathology, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Paul C M S VerhagenDepartment of Urology, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Marjan E van TilDepartment of Clinical Genetics, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Bert EussenDepartment of Clinical Genetics, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Monique LosekootDepartment of Clinical Genetics, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Annelies de KleinDepartment of Clinical Genetics, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Dorien J M PetersDepartment of Human Genetics, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Wilfred F J van IJckenErasmus Center for Biomics, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Harmen J G van de WerkenCancer Computational Biology Center, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Robert ZietseDepartment of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Ewout J HoornDepartment of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Gert JansenDepartment of Cell Biology, Erasmus Medical Center Rotterdam (EMC), Rotterdam, The Netherlands.
Joost H GribnauDepartment of Developmental Biology, Erasmus Medical Center Rotterdam (EMC), Oncode Institute, Rotterdam, The Netherlands.ORCID 0000-0001-5645-4691
Erasmus MC · NLOncode Institute · NLLeiden University Medical Center · NLDDL Diagnostic Laboratory · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal-dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, leading to kidney failure in most patients. In approximately 85% of cases, the disease is caused by mutations in PKD1. How dysregulation of PKD1 leads to cyst formation on a molecular level is unknown. Induced pluripotent stem cells (iPSCs) are a powerful tool for in vitro modeling of genetic disorders. Here, we established ADPKD patient-specific iPSCs to study the function of PKD1 in kidney development and cyst formation in vitro. Somatic mutations are proposed to be the initiating event of cyst formation, and therefore, iPSCs were derived from cystic renal epithelial cells rather than fibroblasts. Mutation analysis of the ADPKD iPSCs revealed germline mutations in PKD1 but no additional somatic mutations in PKD1/PKD2. Although several somatic mutations in other genes implicated in ADPKD were identified in cystic renal epithelial cells, only few of these mutations were present in iPSCs, indicating a heterogeneous mutational landscape, and possibly in vitro cell selection before and during the reprogramming process. Whole-genome DNA methylation analysis indicated that iPSCs derived from renal epithelial cells maintain a kidney-specific DNA methylation memory. In addition, comparison of PKD1+/- and control iPSCs revealed differences in DNA methylation associated with the disease history. In conclusion, we generated and characterized iPSCs derived from cystic and healthy control renal epithelial cells, which can be used for in vitro modeling of kidney development in general and cystogenesis in particular.

Indexed as

Cell LineCellular ReprogrammingDNA MethylationDNA Mutational AnalysisEpigenesis, GeneticEpithelial CellsHumansInduced Pluripotent Stem CellsKidneyKidney TubulesMutationPolycystic Kidney, Autosomal DominantTRPP Cation ChannelsTRPP Cation ChannelsADPKDcystDNA methylationepigenetic memoryiPS cellsPKD1renal epithelial cellssecond hitsomatic mutation

Identifiers

PMID32163234
PMCPMC7103626
OpenAlexW3012326978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.